Mundipharma International Corp. Ltd.’s support of late-stage clinical studies for the once-weekly intravenous echinocandin antifungal, rezafungin, will be transformational for the San Diego, CA-based biotech, Cidara Therapeutics Inc. Inc., under a strategic collaboration between the two companies announced on 3 September and valued at $568m plus royalties.
Cidara's Once-Weekly Antifungal Gets Phase III Boost From Mundipharma
Mundipharma is to provide financial support and development expertise for Cidara’s Phase III clinical studies of its once-weekly echinocandin antifungal for serious infections, in return for ex-US and ex-Japanese marketing rights.
